课题基金 / 基金详情

Clonal CD4 T-Cells in Lung Transplant Recipients

Clonal CD4 T-Cells in Lung Transplant Recipients
肺移植受者中的克隆性 CD4 T 细胞
批准号:
7568904
负责人:
STEVEN R DUNCAN
金额:
$35.58万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2011-01-31

项目摘要

项目成果

STEVEN R DUNCAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Obliterative bronchiolitis (OB) is a frequent and often devastating complication of lung transplantation that is usually refractory to treatments. Although the pathogenesis of OB is clearly immune-mediated, details of these mechanisms remain uncertain. We have recently shown that CD4 T-cells of transplant recipients with OB seem to be invariably characterized by extreme oligclonal proliferations and CD28 downregulation, and these abormalities are largely absent amoung recipients without rejection. We believe these abnormal T- cells play a critical role in development of OB by either causing direct injuries to the allograft, or by orchestrating an inflammatory cascade with elaborations of chemotactic and activating mediators. The projects of this proposal will conduct serial assays of a lung transplant recipient cohort, to establish whether findings of CD4 clonal expansions and CD28 downregulation are useful for diagnosis or prediction of OB. Other studies will characterize these unusual cells and establish their antigen specificities, and delineate their proliferative and cytolytic functions. We have also developed a novel human-murine chimeric model using xenografts of human airways in immunodeficient mice that will enable in vivo assays of immune effects and functions after adoptive transfer of allogeneic (to the airway) human T-cells. We anticipate the focus of these studies on the early events of the immune responses to allografts will result in important new findings that provide insights into the immunopathogenesis of OB. Furthermore, findings here may also open avenues for development of innovative, diagnostic and therapeutic modalities, including earlier and more efficacious interventions to prevent or treat OB.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Rituximab Therapy in Patients with IPF
Rituximab Therapy in Patients with IPF
Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF
  • 批准号:
    10218251
  • 项目类别:
  • 资助金额:
    $52.12万
  • 财政年份:
    2013
  • 负责人:
    STEVEN R DUNCAN
  • 依托单位:
Rituximab Therapy in Patients with IPF
海外基金